GH
Guardant Health, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow -10.9% ·
net new positions +11.1%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 45.42K | $7.92M | n/a | −1 |
| Q2 2026 | 137 | +11 | 93.62M | $13.95B | +17 | −7 |
| Q1 2026 | 130 | -8 | 97.95M | $8.77B | +5 | −14 |
| Q4 2025 | 137 | +1 | 99.79M | $9.86B | +2 | n/a |
| Q3 2025 | 22 | +1 | 50.89M | $3.18B | +2 | −2 |
| Q2 2025 | 19 | -1 | 51.15M | $2.66B | n/a | −1 |
| Q1 2025 | 17 | -1 | 25.07M | $1.07B | n/a | −1 |
| Q4 2024 | 18 | +2 | 25.10M | $766.76M | +2 | n/a |
| Q3 2024 | 15 | +1 | 25.31M | $580.70M | +2 | −1 |
| Q2 2024 | 14 | n/a | 24.13M | $697.01M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 5.45M | -7.2% | $166.47M | 0.1% | ▼ Trim | 3 | SEC ↗ ×4 |
| 2 | Wellington Management ✦ | 4.85M | -52.1% | $148.18M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 3 | State Street Global Advisors ✦ (passive) | 2.85M | n/a | $87.04M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.82M | 0.0% | $86.27M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Two Sigma Investments ✦ | 1.89M | +38.5% | $57.76M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 1.48M | +348.5% | $45.27M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | ARK Investment Management ✦ | 1.44M | -4.8% | $43.99M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 8 | Millennium Management ✦ | 1.23M | +87.6% | $37.48M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 1.19M | +1.1% | $36.44M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 873.08K | New | $26.67M | 0.1% | New | 1 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 503.10K | +14.8% | $15.37M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 279.80K | +392.6% | $8.55M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 96.40K | -88.6% | $2.95M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 45.70K | +267.5% | $1.40M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 15 | PRIMECAP Management ✦ | 43.69K | -34.0% | $1.33M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Marshall Wace ✦ | 32.09K | New | $980,197 | 0.0% | New | 1 | SEC ↗ |
| 17 | Bridgewater Associates ✦ | 12.54K | -30.9% | $383,219 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 7.82K | -48.5% | $238,932 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $26.67M | 0.1% |
| Marshall Wace | $980,197 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 481 holders, 137.05M shares, $11.53B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 116 sh · $19,242
Director · 69 sh · $11,032
Director · 1.10K sh · $192,432
Director · 826 sh · $144,550
Director · 3.30K sh · $578,888
Director · 1.30K sh · $229,236
Director · 971 sh · $172,330
Director · 116 sh · $20,300
Officer · 7.74K sh · $1.38M
Officer · 4.00K sh · $632,193
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology